First off, Recursion was a loooong and often lonely journey for the founders. The idea was met with near-universal skepticism. The company’s entire approach to disease biology was antithetical to conventional thinking in life science. The complexity of the platform was off-putting to both tech and biotech investors for a multitude of reasons. Industry partners simultaneously dismissed the platform for not being relevant and gave feedback that phenotypic screening was played out. The team built Recursion up in the face of tremendous adversity and remained confident in the first principles of the approach and the data that the platform was generating.